LAAO Versus NOAC in Patients with AF and PCI
A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 1386 participants.
Also called NCT05353140
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Not applicable
- Enrolled
- 1,386 participants
- Sponsor
- Registry
-
NCT05353140
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT05353140. Randomized; no masking; primary purpose prevention. Start 2022-09-01 (actual); primary completion 2028-09-20 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- LAAO Versus NOAC in Patients with AF and PCI
- Condition
- Atrial Fibrillation
- Condition
- Percutaneous Coronary Intervention
- Intervention (Device)
- The WATCHMAN/WATCHMAN FLX device
- Intervention (Drug)
- Rivaroxaban + Clopidogre
- Intervention (Drug)
- Aspirin + Clopidogrel
- Lead sponsor
- Xijing Hospital
Record details
- Record id
cardio:ct-nct05353140- Content hash
1dbebab1265f7345042a67f160b84e132b9bd53575c02be0a460fee446ed6060